Accenture Ventures invests in Earli, a biotech company developing early cancer detection.

Accenture Ventures invests in Earli, a biotech firm pioneering early cancer detection. Earli's synthetic targeting platform uses programmable genetic constructs to detect cancer cells early, increasing sensitivity and specificity. This approach may lead to faster, personalized treatments and support Earli's expansion of collaborations with global health and pharma companies.

August 19, 2024
3 Articles